Navigation Links
Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold
Date:10/6/2011

LAS VEGAS, Oct. 6, 2011 /PRNewswire/ -- This is being released by SCM:

(Photo:  http://photos.prnewswire.com/prnh/20111006/LA81891)

After 7 weeks of testimony and 4 hours of closing statements, lead trial attorney for the plaintiffs in the hepatitis C trial in Clark County Nevada, Robert Eglet, asked jurors to bring a verdict of $10 million in compensatory damages for Anne Arnold, $2.5 million in compensatory damages for James Arnold and to consider whether the Arnolds should receive punitive damages. 

Attorney Robert Eglet told jurors, corporate greed dictated the actions of the drug company Teva Pharmaceuticals. "The primary concern should be the safety of the patient. A responsible drug company should design, package and market the drug to reduce human error. The drug companies knew there was a problem with the jumbo infusion 50mL vials of Propofol in these endoscopy centers," said Eglet.

Eglet told jurors that every 50mL vial of Propofol was sent to the endoscopy centers with a vent spike labeled for multi dosing.  "The temptation and opportunity is too great for misuse and the drug company knew this. They took no steps to prevent this. They did nothing and Teva expert witnesses Craig Lea and Rosalie Lowe in depositions agreed that health care providers using 50mL vials in an endoscopy center create more of a proclivity to multi dose," said Eglet.  

Attorney Robert Eglet told the jury that production of the sedative Propofol was stopped within 3 weeks of the unprecedented $500 million verdict in the Chanin trial in May 2010. Teva Vice President, Craig Lea admitted under examination by Eglet that Teva turned the lights out in their Propofol plant 21 days after last year's verdict. 

The jury is now in deliberation.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor.


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):